Canadian International Pharma Corp. Announces Non-brokered Private Placement

CANADIAN INTERNATIONAL PHARMA CORP.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR

DISSEMINATION IN THE UNITED STATES

Trading symbol: TSX-V – NEX: CIP.H

Canadian International Pharma Corp. Announces Non-brokered Private Placement

Vancouver, British Columbia – October 6, 2020 – Canadian International Pharma Corp. (the “Company”)

announces that, further to the news release of Augu st 21, 2020 and subject to regulatory approval, the

Company intends to proceed with the previously announced non-brokered private placement financing

(the “Financing”) of up to 8,888,888 units (each, a “Unit”) at a price of $0.1125 per Unit for gross proceeds

o f u p t o $ 1 , 0 0 0 , 0 0 0 . E a c h U n i t c o n s i s t s o f o n e c o m m o n s h a r e ( o n a p o s t c o n s o l i d a t e d b a s i s a f t e r

completion of its 1 for 10 consolidation announced on August 21, 2020)(each, a “ Share”) and one share

purchase warrant (each, a “Warrant”). One Warrant entitles the holder thereof to purchase one additional

post-consolidation Share at a price of $0.15 per post -consolidation Share for a period of one year from

closing of the Financing.

The proceeds from the Financing will be used for general working capital.

All securities issued in connection with the Financing will be subject to a statut ory hold period expiring

four months and one day after closing of the Financ ing. Completion of the Financing is subject to a

number of conditions, including, without limitation, receipt of all regulatory approvals, including

approval of the TSX Venture Exchange.

None of the securities sold in connection with th e Financing are registered under the United States

Securities Act of 1933, as amended, and no such secu rities may be offered or sold in the United States

absent registration or an applicable exemption from the registration requirements. This news release shall

not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the

securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For further information, contact Douglas L. Mason at 604.922.2030

CANADIAN INTERNATIONAL PHARMA CORP.

“Ron Schmitz”

Ron Schmitz, Director

Neither the TSX Venture Exchange nor it s Regulation Services Provider (as that term is defined in policies of the

TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.